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Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently
inadequately controlled despite intensive guideline-based therapy. Targeting allergic inflam-
matory processes that underlie the pathogenesis of severe persistent asthma improves asthma
control in a significant proportion of patients. Omalizumab, a humanized monoclonal anti-
immunoglobulin E (IgE) antibody, has been developed to target IgE, which is central to trig-
gering and maintaining allergic airway inflammation. In a comprehensive program of clinical
trials, omalizumab has been shown to reduce asthma exacerbation and emergency visit rates,
and to improve quality of life in patients with severe persistent allergic asthma. It is difficult to
predict which patients would most benefit from omalizumab treatment; accurate selection
and dosing of patients are essential to achieve benefit. Patients need to have convincing
IgE-mediated asthma and be dosed according to pre-treatment serum total IgE level and body
weight, using a specified dosing table. Based on clinical trial data analysis, it is recommended
that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment
should only be continued in responders, i.e. those judged by the physician to have achieved
a marked improvement or complete asthma control. Omalizumab is generally well tolerated.
Anaphylactic-like reactions are rare (0.1% of patients) and less common than encountered with
other biologics.
ª 2009 Published by Elsevier Ltd.) 23 8079 6960; fax: þ44 (0) 23 8070 1771.
c.uk (S. Holgate).
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Omalizumab in clinical practice 1099Scope of review
Several reviews have been published recently on the effi-
cacy and safety of omalizumab in the treatment of
adolescents and adults with moderate-to-severe allergic
(IgE-mediated) asthma.1e4 Additional reviews have dis-
cussed the anti-inflammatory effects of omalizumab5 as
well as the cost-effectiveness of omalizumab in the treat-
ment of severe allergic asthma.6 This publication is inten-
ded to provide a review of the literature pertaining to
potential issues around the safety of omalizumab, high-
lighted in the prescribing information, as well as data in the
public domain.
Methodology
In selecting studies to include in this review, a literature
search for relevant material was conducted using the
MedLine database (1970e2008). Publications which
addressed or provided insight into the areas for discussion
were hand-picked, including some which were funded by
the manufacturer of omalizumab to address questions from
regulatory authorities during the licensing process.
Introduction
Asthma is a serious health problem that affects people of
all ages throughout the world.7 The Global Initiative for
Asthma (GINA) treatment guidelines emphasize that clinical
management should be based on clinical control rather
than asthma severity, which can change over time. Asthma
control is defined in the latest update of the GINA guide-
lines (2007) as no daytime symptoms, no limitations of daily
activities, no nocturnal symptoms, no need for reliever
treatment, normal or near-normal lung function and no
exacerbations.7 GINA guidelines recommend that controller
medications, i.e. daily treatment to keep asthma under
control, be tailored for each patient in a stepwise approach
(Fig. 1).7 Reliever medications, i.e. those that act quickly
to reverse bronchoconstriction and relieve its symptoms,
are used on an as-needed basis.7
Although mild and moderate persistent asthma can
generally be controlled with inhaled corticosteroids (ICS)
and long-acting b2-agonists (LABAs), severe persistent
asthma is often inadequately controlled despite these
treatments.7,8 Furthermore, many patients with severe
asthma still fail to achieve complete control despite using
additional controller medications, such as leukotriene
modifiers (LTRAs) or theophylline.7 In the Gaining Optimal
Asthma Control (GOAL) study, 38% of patients with the most
severe asthma (defined as a daily dose of 500e1000 mg
beclometasone; nZ 568) remained inadequately
controlled despite optimized treatment with ICS and a LABA
(fluticasone and salmeterol).9 In addition, 31% of patients
still remained inadequately controlled despite the addition
of a 4-week course of oral corticosteroids (OCS) to the
treatment regimen on completion of the 1-year study. In an
observational study (Epidemiological Study of Xolair Eval-
uating Clinical Effectiveness and Long-Term Safety in
Patients with Moderate-to-Severe Asthma [EXCELS]) of the
long-term clinical safety and effectiveness of theanti-immunoglobulin E (anti-IgE) antibody, omalizumab,
the entry characteristics of the 5067 patients in the oma-
lizumab cohort with moderate or severe allergic asthma
were analysed using the asthma control test (ACT; a 5-item,
self-administered survey designed to provide a broad
assessment of asthma control over the previous 4 weeks).
The scores showed that asthma was well controlled in less
than half of patients (45%), while 29% were not well
controlled and 26% were poorly controlled.10
Patients with severe asthma are at a high risk of asthma-
related hospitalization and mortality.11e14 In addition, both
impairment in quality of life15e17 and economic burden16e18
increase with increasing asthma severity and are greatest in
patients with inadequately controlled severe persistent
allergic asthma.16,19 In 1998 in a northern area of Spain, it
has been estimated that severe asthma accounted for at
least half of the direct and indirect costs associated with
asthma.20 There is, therefore, an urgent need for improved
treatment options that will provide asthma control in these
patients.
Based on findings from a European cross-sectional
observational study (ENFUMOSA), approximately 50% of
patients with severe asthma had a positive skin-prick test
for common aeroallergens.21 New treatment options that
target allergic inflammatory processes in patients with
severe persistent asthma may, therefore, provide a means
to reduce the considerable individual and social burden of
this inadequately controlled disease.Allergic asthma and IgE
Asthma is an inflammatory disorder of the airways that
involves several inflammatory cells and the interaction of
many different mediators.7 Allergic asthma is characterized
by the presence of IgE antibodies against common allergens
such as house dust mite, animal dander, pollens and
moulds.7 Initial allergen exposure results in polarization of
the T lymphocyte response to a Th2 phenotype with the
secretion of IL-4 and IL-13. This, combined with these
cytokines from mast cells, initiates the isotype switching of
IgM to the corresponding IgE directed to epitopes that may
cover several loops of the allergen protein. Sensitization
involves the processing of allergens by professional antigen-
presenting cells and the presentation of small linear
peptide epitopes to the T-cell receptor along with co-
stimulation involving CD80/86 interacting with B6 on naive
T cells.22
Subsequent exposure causes the synthesis of allergen-
specific IgE, which binds to high-affinity receptors (Fc3RI)
on mast cells and basophils.23 The cross-linking of two IgE
molecules by the allergen triggers cell activation and
degranulation, with the release of pre-formed mediators,
such as histamine, heparin, and neutral proteases as well as
newly formed mediators that include prostaglandin D2,
leukotriene C4, adenosine and tumour necrosis factor
(TNF)-a.23,24 Subsequent synthesis and release of inflam-
matory mediators, e.g. interleukin (IL)-4, IL-5 and IL-13,
promote leukocyte adhesion and, with the release of che-
mokines, the infiltration of circulating cells e primarily
eosinophils, basophils and Th-2 cells e into the tissues,
resulting in the characteristic symptoms of asthma.23e25
Figure 1 The GINA guidelines recommend a stepwise approach to controller medication based on level of control.7 aPreferred
controller options as shown in shaded boxes; bReceptor anatagonists or synthesis inhibitors. ICS, inhaled corticosteroid; LABA, long-
acting b2-agonist.
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Mechanism of action
Omalizumab inhibits the binding of IgE to Fc3RI receptors on
mast cells and basophils.5,26e28 Free IgE levels are rapidly
reduced and, with less IgE available to bind, the expression
of Fc3RI on inflammatory cells, such as basophils, mast cells
and dendritic cells, is down regulated (Fig. 2).23,27,29
Interrupting the interaction between IgE and Fc3RI inhibits
mast-cell and basophil activation and the subsequentFigure 2 Proposed mechanismrelease of their inflammatory mediators. A reduction in IgE
binding also leads to down-regulation of the cell surface
expression of IgE and Fc3RI in the airway mucosa and
reduces both sputum and tissue eosinophilia.26 By pre-
venting the release of mast cell-derived mediators, omali-
zumab may reduce inflammatory cell recruitment
(particularly eosinophils), tissue remodelling and functional
changes in the airways.30,31
Because the binding site of omalizumab is buried within
the Fc3RI receptor, it cannot bind to IgE that is already
attached to mast cells and basophils.32,33 Consequently,s of action of omalizumab.5
Table 1 Adverse reactions with omalizumab in clinical
trials.42
Infections and infestations
 Rare Parasitic infection
Immune system disorders




 Uncommon Dizziness, somnolence, paraesthesia,
syncope
Vascular disorders
 Uncommon Postural hypotension, flushing
Respiratory, thoracic and mediastinal disorders
 Uncommon Pharyngitis, coughing, allergic
bronchospasm
Gastrointestinal disorders
 Uncommon Nausea, diarrhoea, dyspeptic signs
and symptoms
Skin and subcutaneous tissue disorders
 Uncommon Urticaria, rash, pruritus,
photosensitivity
General disorders and administration site conditions
 Common Injection-site reactions such as pain,
erythema, pruritus, swelling
 Uncommon Weight increase, fatigue, swelling
arms, influenza-like illness
Frequencies are defined as: common (>1/100; <1/10),
uncommon (>1/1,000;< 1/100) and rare (<1/1,000).
Omalizumab in clinical practice 1101omalizumab is not able to cross-link Fc3RI receptors and
initiate the release of inflammatory mediators.
Clinical pharmacology
Omalizumab is absorbed slowly after subcutaneous adminis-
tration, reaching peak serum concentrations after a mean of
7e8 days.29 Clearance is slow (mean 2.4 1.1 mL/kg/day)
with a terminal half-life (t1/2) of 26 days. No clinically impor-
tant changes in the pharmacokinetics of omalizumab have
been observed as a result of differences in age, sex or race.
Treatment with omalizumab has been shown to result in
dose-dependent reductions in serum free IgE concentra-
tions within 1 h of dosing. In phase III studies, the mean
maximal decreases in serum free IgE were found to be
greater than 96% of baseline levels.34 Studies in patients
with allergic asthma or rhinitis showed that clinical benefits
with omalizumab are observed when serum free IgE levels
are reduced to 50 ng/mL (20.8 IU/mL).35e37 However, the
ability of omalizumab to reduce free IgE levels to these
levels is dependent on dose, the patient’s weight and
baseline serum total IgE level.38 The target average free IgE
level has been set at 25 ng/mL (10.4 IU/mL) to ensure that
at least 95% of patients achieve a level below 50 ng/mL
(20.8 IU/mL).38 A dosing table has been developed to
facilitate calculation of the omalizumab dose required to
achieve the target reduction in free IgE, and is explained in
more detail in the Dosing and administration section below.
Efficacy
Omalizumab is effective in patients with severe persistent
allergic (IgE-mediated) asthma who are inadequately
controlled despite optimized therapy (i.e. high-dose ICS
plus LABA additional controller medication; GINA treat-
ment step 4) and who have had multiple documented
exacerbations in the previous year.7,39 The INvestigatioN of
Omalizumab in seVere Asthma TrEatment (INNOVATE) study
evaluated the efficacy of omalizumab during 28 weeks of
treatment in 419 patients with inadequately controlled,
severe persistent allergic asthma despite optimized
therapy.39 Add-on omalizumab reduced the rate of clini-
cally significant asthma exacerbations (asthma worsening
requiring systemic corticosteroids) by 26% (PZ 0.042) and
severe exacerbations (peak expiratory flow [PEF] or forced
expiratory volume in 1 s [FEV1] <60% personal best and
requiring systemic corticosteroids) by 50% (PZ 0.002),
compared with placebo.39 In addition, the rate of emer-
gency visits (hospital admissions, emergency room visits
and unscheduled doctor’s visits) was reduced by 44%,
compared with placebo (PZ 0.038). Based on these data,
the number needed to treat (NNT) to prevent one clinically
significant exacerbation per year is 2.7, and the NNTs to
prevent one severe exacerbation and one emergency visit
are 2.0 and 2.8 respectively.40 Omalizumab also led to
significant improvements in lung function (PEF, PZ 0.042;
FEV1 (% of predicted), PZ 0.043) and asthma symptoms
(PZ 0.0398) compared with placebo.
The findings of the INNOVATE study have been confirmed
in a pooled analysis of seven efficacy trials involving a total
of 4308 patients with predominantly severe persistentallergic asthma (93% had severe disease according to the
GINA 2002 classification7,41). As in INNOVATE, omalizumab
was administered as add-on therapy to current optimized
asthma treatment in all seven studies. Add-on omalizumab
was compared with placebo in five double-blind studies and
with current asthma therapy alone in two open-label
studies. Omalizumab-treated patients had an annualized
asthma exacerbation rate of 0.91, compared with 1.47 in
the control group (38.3% reduction; P< 0.0001). The pooled
analysis also showed a significant reduction (47%) in the
need for emergency medical care in those patients treated
with omalizumab (P< 0.0001 compared with controls).
Safety, warnings and precautions
Omalizumab is well tolerated with a frequency and severity
profile of adverse events (AEs) similar to that seen in
patients receiving placebo or best available therapy.42 AEs
by system organ class and frequency for the total safety
population treated with omalizumab in clinical trials are
shown in Table 1. In controlled studies, a total of 2111
patients received omalizumab for 6 months, and 555 for at
least 1 year.42 The most frequently reported AEs with
omalizumab were upper respiratory tract infection (16%),
headache (16%), nasopharyngitis (14%) and sinusitis (10%).
The majority of AEs were of mild-to-moderate severity and
short duration. Injection-site reactions (of any severity)
occurred in 45% of omalizumab-treated patients and 43% of
placebo-treated patients, while severe injection-site
1102 S. Holgate et al.reactions occurred in 12% and 9% of omalizumab- and
placebo-treated patients, respectively. Discontinuations
due to AEs were uncommon (omalizumab 2%, control 1%)
and the incidence of suspected drug-related AEs in placebo-
controlled allergic asthma studies was similar in the oma-
lizumab and placebo groups (9.2% vs 7.6%, respectively).
Serious AEs were similar in omalizumab and control pop-
ulations (omalizumab 4.2%, control 3.6%).
Allergic reactions
In clinical trials, anaphylaxis was reported in three out of
3507 (0.1%) patients: occurring with the first dose of oma-
lizumab in two patients and with the fourth dose in one
patient.34 The time to onset of anaphylaxis was 90 min
after administration in two patients and 2 h after adminis-
tration in one patient. Based on post-marketing reports
submitted to the Food and Drug Administration’s Adverse
Event Reporting System database and the manufacturers of
omalizumab and cases published in the literature, 124 cases
of anaphylaxis were identified in an estimated population
of 57,300 patients who had received omalizumab in the
United States between June 2003 and December 2006
(reporting rate 0.2%).43 Approximately one-quarter of these
patients had a prior history of anaphylaxis. Eighty-nine
percent of patients displayed respiratory symptoms, 14%
developed hypotension or syncope, and 19% required
hospitalization. Several cases had a delayed onset, with
symptoms occurring up to, and even beyond 24 h post-
administration (Fig. 3). Anaphylactic events were reported
after the second, third or more than third dose of omali-
zumab. The majority of patients responded to epinephrine,
but several patients required multiple doses of epineph-
rine, bronchodilators and H1-antihistamines. Anaphylaxis
recurred in 78% of patients (18 out of 23) who were re-
challenged with omalizumab. While it is possible to spec-
ulate on the mechanism (or mechanisms) of anaphylaxis
with omalizumab based on evidence from published case
studies, further studies are still needed. One report44 sug-
gested that reactions may be related to the excipient
polysorbate rather than the omalizumab molecule itself,45Figure 3 Time to onset of anaphylaxis cases (n Z 124) in an
estimated 57,300 patients who have received omalizumab in
the United States.43while reports of a lack of anti-omalizumab antibodies44,46
and elevated circulating tryptase levels46 may suggest
mediator release from mast cells.
According to the EU label, it is recommended that
medications should always be available for immediate use
for the treatment of anaphylactic reactions following
administration of omalizumab. In addition, patients should
be warned of the potential for such reactions and, if
allergic reactions occur, informed to seek prompt medical
attention. Further recommendations for physicians
regarding the patient observation period following omali-
zumab administration, including patient education on
anaphylaxis, are provided in the report developed by the
Omalizumab Joint Task Force (OJTF; The American
Academy of Allergy, Asthma and Immunology and the
American College of Allergy, Asthma and Immunology
Executive Committees).47,48 These include:
 Obtaining informed consent after discussing the risks,
benefits and alternatives to omalizumab with the
patient.
 Educating the patient regarding the signs, symptoms
and treatment of anaphylaxis (Table 2).49
 Ensuring the patient is educated on the proper use of
the epinephrine autoinjector and advised to carry this
pre-administration and for 24 h post administration.
 Assessing the patient’s current health status before
each injection, including vital signs and some measure
of lung function (e.g. PEF or FEV1).
 The OJTF recommends that patients be kept under
observation for 30 min after each injection. This time
should be extended to 2 h for the first three injec-
tions.47,50 However, this could be modified based on
a physician’s clinical judgment after discussing risks
with the patient.
As with all recombinant DNA-derived humanized mono-
clonal antibodies, patients may in rare cases develop
antibodies to omalizumab. In an analysis of all data
collected from clinical trials up to November 2002, no cases
of immunoreactivity to omalizumab have so far been found
in those receiving omalizumab either subcutaneously or
intravenously, however, one case has been detected in
a patient who received omalizumab in an aerosolized
form.34 The development of antibodies may potentially
lead to significant drug interference.
Serum sickness
When omalizumab binds to free IgE, small complexes of
three or six molecules (trimers or hexamers) are formed.51
Large immune complexes are a potential concern for the
development of serum sickness, but the relatively small
size of omalizumab-IgE trimeric and hexameric complexes
and their inability to activate the complement cascade
means that they are easily cleared from the body by the
reticulo-endothelial system in the liver, bone marrow and
spleen. While no AEs were reported as serum sickness in the
omalizumab safety database, a search for event clusters
that might be indicative of serum sickness revealed three
omalizumab-treated patients and one control patient with
serum sickness-like symptoms.52 Additionally, one case
Table 2 Anaphylaxis education sheet.
Treatment of anaphylaxis in the physician’s office48 Treatment of anaphylaxis in the community49
Immediate measures
Assess airway breathing, circulation and orientation
Patient self-management after leaving the physician’s office
Information sheet on anaphylaxis with specific information
on omalizumab
Epinephrine autoinjector (EpiPen duopak or Twinject)
Inject epinephrine, 0.3 mg intramuscularly, in the vastus
lateralis (lateral thigh)
Activate emergency medical services (call 911 or local
rescue squad)
Anaphylaxis Emergency Action Plan (downloadable from
www.AAAAI.org)
Place patient in recumbent position and elevate the lower
extremities, as tolerated
Establish and maintain airway Administer oxygen
Establish an intravenous line for venous access and fluid
replacement; keep open with normal saline
Consider administration of nebulized albuterol, 2.5e5 mg
in 3 mL of saline; repeat as necessary
Consider administration of ancillary medications, such as H1
antihistamine or a systemic corticosteroid
Anaphylaxis wallet card (available from www.AAAAI.org at
no charge to members and minimal charge for
non-members)
Medical identification jewellery tag (e.g. MedicAlert
bracelet)
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zumab has been published.53
Malignancies
Malignant neoplasms were reported in 20 of 5015 (0.5%)
omalizumab-treated patients and five of 2854 (0.2%) control
patients.54 No cases of malignant neoplasia were considered
drug-related when carefully assessed by a panel of inde-
pendent oncologists, blinded to treatment assignment.54 The
overall observed incidence rate of malignancy in the omali-
zumab clinical trial programme was comparable to that
reported in the general population: comparison with the
National Institutes of Health (NIH) Surveillance, Epidemi-
ology, and End Results (SEER) database showed that the
standardized incidence ratio (95% confidence interval [CI]) of
observed to expected number of malignant neoplasia events
in the omalizumab group was 0.99 (0.55, 1.63) compared
with 0.31 (0.04, 1.11) in the control group.54 The diversity in
the type of cancers observed, the relatively short duration of
exposure and the clinical features of the individual cases
make it most unlikely there is a causal relationship between
omalizumab and malignancies.
Parasitic (helminth) infections
Although it is believed that IgE is involved in host defence
mechanisms against parasitic infection, the overall helminth
infection rate in the omalizumab clinical trial programmewas
found to be less than 1 in 1000 (Novartis, data on file). A slight
increase in infection rate in patients receiving omalizumab
was reported in one exploratory, randomized, double-blind,
placebo-controlled trial in patients with allergic asthma or
rhinitis and at high risk of parasitic infection.55 Nevertheless,
the time course, severity and response to treatment of
infection were unaffected by omalizumab treatment.
However, cautionmay bewarranted in patients at high risk ofhelminth infection, in particular those travelling to areas
where helminthic infections are endemic. If patients do not
respond to recommended anti-helminth treatment, discon-
tinuation of omalizumab should be considered.Churg-Strauss syndrome and hypereosinophilic
syndrome
Patients with severe asthmamay rarely present with systemic
hypereosinophilic syndrome or allergic eosinophilic granulo-
matous vasculitis (Churg-Strauss syndrome),bothofwhichcan
usually be treated with systemic corticosteroids. As when
treatingwith other anti-asthma therapies, physicians treating
with omalizumab should be alert to the development of
marked eosinophilia, vasculitic rash, worsening pulmonary
symptoms, cardiac complications and/or neuropathy.Selection of patients for omalizumab
treatment
Omalizumab is indicated in the EU as add-on therapy to
improve asthma control in patients (12 years of age and
above) with severe persistent allergic asthma who have the
following characteristics:
 A positive skin test or in vitro reactivity (radioallergo-
sorbent test [RAST]) to a perennial aeroallergen.
 Reduced lung function (FEV1< 80%).
 Frequent daytime symptoms or night-time awakenings.
 Multiple documented severe asthma exacerbations.
 Receiving daily high-dose ICS plus a LABA (Fig. 4).
Omalizumab is included in the GINA 2007 guidelines at
step 5, along with maintenance OCS, as an add-on therapy to
high-dose ICS plus LABA. However, it is the only GINA step 5
1104 S. Holgate et al.add-on therapy with Category A evidence, i.e. a rich body of
evidence from randomized controlled trials.7 It should be
noted that in the US, omalizumab is indicated for patients
aged at least 12 years, who have moderate-to-severe
persistent asthma with a positive skin test of in vitro reac-
tivity to a perennial aeroallergen and are inadequately
controlled using ICS. As described in the EU label, omalizu-
mab treatment should only be considered for patients with
convincing lgE-mediated asthma. Prescribing physicians
should therefore ensure that patients with lgE below 76 IU/
mL have an unequivocal RAST to a perennial allergen before
starting therapy.
Predicting response
It is difficult to predict which patients will have the
greatest benefit from treatment with omalizumab based on
pre-treatment characteristics. The most accurate means of
ensuring that omalizumab treatment is beneficial is to
evaluate the response after a 16-week therapeutic trial
(see Evaluating clinical response below).
Baseline IgE is the only variable found to have a broad
predictive value based on extensive multi-variate analysis of
data from the INNOVATE study. A lower baseline IgE was
associated with a smaller treatment benefit (Table 3).56
Subgroup analysis of the pooled population of patients
enrolled in seven clinical trials (including INNOVATE) indi-
cated that omalizumab reduced asthma exacerbation rates
across four IgE quartiles: (1) 0e75 IU/mL; (2) 76e147 IU/mL;
(3) 148e273 IU/mL; and (4) 274 IU/mL, but reached
statistical significance in the three upper IgE quartiles only
(P< 0.001).56 Similarly, total emergency visit rates, propor-
tions of responders with meaningful Asthma Quality of LifeFigure 4 Selecting patients for omalizumab therapy. ICS, inha
expiratory volume in 1 s; RAST, radioallergosorbent test; IgE, immuQuestionnaire (AQLQ) improvements and FEV1 net benefit
favoured omalizumab-treatedpatients in the three upper IgE
quartiles. However, for other outcomes there were benefits
across all four quartiles, including severe exacerbation rates
(statistically significant differences in quartiles 1, 3 and 4;
P< 0.05) and thephysician’s overall assessment (statistically
significant benefits in all IgE quartiles; P< 0.05).
No consistent predictive effect for omalizumab response
has been observed for either total specific IgE load or for
levels of IgEs specific for individual allergens (dust mite
[Dermatophagoides pteronyssinus and Dermatophagoides
farinae], cat dander, dog dander, cockroach, Blatella ger-
manica and Blatella orientalis, Aspergillus fumigatus, and
Alternaria alternata), either singly or in combination.57
However, additional studies are required to further inves-
tigate and confirm these findings.
Dosing and administration
Dose determination
Dosing is determined by serum total IgE levels measured
before initiation of omalizumab treatment and the
patient’s body weight, using a dosing table (Fig. 5). Once
baseline serum IgE levels have been measured, it is not
necessary to re-test IgE levels during treatment (total IgE
levels rise and remain elevated during omalizumab treat-
ment). However, dose adjustments will be necessary if
there is a significant change in the patient’s body weight. If
this occurs, the pre-treatment serum IgE level and new
body weight should be used to recalculate the dose.
More than double the number of under-dosed patients
discontinued omalizumab therapy due to unsatisfactoryled corticosteroid; LABA, long-acting b2-agonist; FEV1, forced
noglobulin E.
Table 3 Efficacy outcomes in subgroups of patients divided in quartiles according to baseline IgE in the pooled population.56
Outcome measure Baseline IgE subgroup



















1.28 1.48 0.85 1.47 0.80 1.47 0.76 1.43
Da D 13.8% D 41.9% D 45.4% D 46.5%
P-value 0.227 <0.001 <0.001 <0.001
Annualized severe
exacerbation rate
0.09 0.22 0.07 0.11 0.07 0.20 0.05 0.17
Da D 59.7% D 38.0% D 66.4% D 68.8%
P-value <0.05 0.218 <0.001 <0.001
Annualized total
emergency visit rate
0.44 0.64 0.32 0.60 0.35 0.89 0.33 0.55
Da D 31.0% D 46.3% D 60.9% D 40.8%
P-value 0.141 <0.05 <0.01 <0.05
FEV1 net benefit,
b % 4.1 0.5 11.7 3.4 7.9 0.5 22.3 2.9
P-value 0.289 0.057 0.099 <0.001
AQLQ improvement 0.5 points, % 58.7 54.2 67.5 54.0 68.7 50.0 68.9 52.5
P-value 0.298 <0.001 <0.001 <0.001
Physician’s overall assessment,c % 49.3 40.2 59.3 42.9 66.6 36.1 67.1 36.2
P-value <0.05 <0.001 <0.001 <0.001
a D Denotes the reduction in rate for omalizumab vs placebo.
b Patients with improvement in FEV1 200 mL minus those with worsening 200 mL, statistical testing was performed using propor-
tions of patients with an improvement, a worsening, or no meaningful change.
c Complete control or marked improvement, P-value for the overall distribution of physician’s overall assessment. Not all endpoints
were assessed in each study.
Omalizumab in clinical practice 1105therapeutic effect, compared with correctly dosed patients
(i.e. 36.4% vs 15.0%) in a historic-prospective study of 147
patients in France who had received a nominative tempo-
rary use authorisation (ATU) for omalizumab between July
2003 and January 2006.58 It is, therefore, essential that the
correct dose of omalizumab is calculated and administered
for each individual patient.
Preparation and administration
Omalizumab is provided as a sterile, white, preservative-
free, lyophilized powder, which requires reconstituting
with water. It should be administered as a subcutaneous
injection every 2 or 4 weeks by a healthcare provider only.
The solution is slightly viscous and the injections can take
up to 30 s to administer. They are usually administered in
the deltoid region of the arm or in the thigh. Each omali-
zumab vial is intended for single use only. Once recon-
stituted, omalizumab can be stored for up to 4 h at room
temperature or up to 8 h in the refrigerator (2e8 C).
Reconstituted omalizumab vials also need to be protected
from direct sunlight.
Dosing in patients with low or high IgE levels
The dosing schedule for omalizumab is based on the need to
decrease free IgE levels. According to the EU label, theminimum baseline total IgE required for omalizumab
treatment is 30 IU/mL. Although a clinical response to
omalizumab was seen at all baseline IgE levels in the
INNOVATE study, a response was less likely if the baseline
IgE was below 76 IU/mL.56 Patients with lower baseline
total IgE may have, in general, lower levels of allergen-
specific IgE and consequently might have a lower potential
to respond to anti-IgE treatment.
At present, the dosing table for omalizumab is based on
a maximum dose of 750 mg every 4 weeks, which precludes
treatment of patients with IgE levels above 700 IU/mL.
Studies are being conducted to investigate the treatment of
patients with higher IgE levels (700e1500 IU/mL).Evaluating clinical response
The physician’s overall assessment (a composite measure
that encompasses multiple aspects of response including
patient interviews, review of medical notes, spirometry
and diaries of symptoms, rescue medication use and peak
expiratory flow) at 16 weeks has been determined to be the
most meaningful measure for identifying responders and
determining whether to continue treatment with omalizu-
mab.56 Only patients judged by the physician to have
responded to therapy (i.e. shown a marked improvement in
asthma control or complete asthma control) should
Figure 5 Omalizumab dosing table. IgE, immunoglobulin E.
f Defined in this study as those patients achieving 0.5-point
improvement in Mini-AQLQ overall score at 27 weeks, as data
relating to the physician’s overall assessment was not collected in
the original study.
1106 S. Holgate et al.continue therapy, as specified in the EU label (but not the
US label) for omalizumab. Non-responders are categorized
as those with discernible but limited control, no appre-
ciable change or a worsening in control.56 This also
complies with current guideline recommendations for
regular clinical review of patients with persistent asthma.7
In the EU, recommendation for using the physician’s
overall assessment to identify potential responders to
omalizumab treatment is based on an analysis of the
INNOVATE data and a pooled analysis that also included
data from four additional randomized, double-blind,
placebo-controlled clinical trials of 24 weeks’ duration.
This analysis identified 61% of patients as responders to
omalizumab using the physician’s overall assessment and
provided accurate discrimination of exacerbation rates and
other outcomes measures in responders vs non-responders
(Table 4).56 ‘‘Responders’’ were defined as those with
marked improvement or complete control (graded in a five-
level evaluation). In responders, annualized rates of clini-
cally significant exacerbations were reduced by 60% (0.73 vs
1.84, P< 0.001 vs placebo), severe exacerbations by 76%
(0.13 vs 0.54, P< 0.001 vs placebo) and total emergency
visits by 76% (0.20 vs 0.85, P< 0.0001) (Novartis, data on
file). These reductions illustrate the value of response
evaluation when compared with the overall omalizumab-
treated population in the INNOVATE study (reductions of
26%, 50% and 44%, respectively) at 28 weeks.39 It should be
noted, however, that using the asthma-related quality oflife questionnaire (AQLQ) a high proportion of responders (%
patients with 0.5 point increase in total AQLQ score59,60)
was also identified, but this measure was not discriminative
for severe exacerbation response. The Asthma Control
Test61 may also be a useful tool to assess response to
omalizumab therapy; however, it was not available when
the INNOVATE study was carried out. The test is being
examined in ongoing studies.
The improved outcomes in responders in the 28-week,
placebo-controlled INNOVATE study39 have been confirmed
by a post-hoc analysis62 of the severe allergic asthma
subpopulation from a 1-year, randomized, open-label
study.63 In the overall omalizumab-treated population of
this study (nZ 115) compared with those receiving best
standard care only (nZ 49), annual asthma exacerbation
rate was reduced by 59% (1.26 vs 3.06; P< 0.001); asthma
deterioration-related incident (ADRI) rate was reduced by
40% (5.61 vs 9.40; P< 0.05) and significant improvements
were seen in lung function, asthma symptom scores and
Mini-AQLQ overall score (P< 0.05). In the 70% of omalizu-
mab-treated patients (71/102) who respondedf to treat-
ment, compared with best standard care, exacerbation
rate was reduced by 64% (1.12 vs 3.07; P< 0.001), ADRI rate
Table 4 Annualized exacerbation rates, unscheduled healthcare utilization and other asthma control measures by physician’s
overall assessment responders and non-responders to omalizumab (INNOVATE study).56
Responder Non-responder
Clinically significant exacerbations
Rate, mean (SD) 0.6 (1.31) 2.6 (6.39)
Severe exacerbations 0.2 (0.6) 1.4 (6.1)
Rate, mean (SD) 0.4 1.1
Hospitalizationsa
Patients hospitalized in treatment phase, % 2.5 9.1
Rate, mean (SD) 0.03 (0.22) 0.10 (0.35)
Emergency room visitsa
Rate, mean (SD) 0.02 (0.17) 0.17 (0.80)
Unscheduled physician visitsa
Rate, mean (SD) 0.11 (0.44) 0.49 (1.31)
Any unscheduled healthcare utilization
Rate, mean (SD) 0.20 (0.61) 1.50 (6.14)
Asthma symptom score, mean (SD)b 1.24 (1.82) 0.47 (1.72)
Night awakenings due to asthma, per week mean (SD)b 1.23 (2.22) 0.28 (2.74)
Daily rescue medication use, puffs mean (SD)b 2.32 (3.93) 0.17 (3.79)
FEV1 (mL), mean (SD)
b 252 (521) 87 (445)
AQLQ improvement 0.5-point, % of patients 78.8 34.7
a Rates in the previous year were similar for responders and non-responders.
b Values are changes from baseline.
Omalizumab in clinical practice 1107was reduced by 50% (4.71 vs 9.33; P< 0.001) and further
improvements were seen in all other outcomes. The
investigators proposed that this responder data, as assessed
by a physician, reflects the actual benefit of omalizumab
seen in clinical practice.
In the UK, an algorithm has been developed to assist
physicians in determining patient response to omalizumab
therapy following advice from the Scottish Medical Council
(SMC) during reimbursementdiscussions. The SMC felt that the
physician’s overall assessment was too subjective, and physi-
cians would benefit from a more robust guidance on assessing
response.The resulting algorithmstates that thefinal decision
to continue with omalizumab therapy should be based on key
assessment criteria (ACT, Mini-AQLQ and Physician Global
Evaluation of Treatment Response), with supportive criteria
(PEF, exacerbations and unscheduled healthcare utilization
[HCU]) to aid physicians in the assessment of overall asthma
control and lung function (Fig. 6).64
The recommended 16-week evaluation period is consis-
tent with the mechanism of action of omalizumab and the
progressive onset of action seen in clinical trials. A plateau of
improvement in asthma symptoms and morning PEF has been
identified at around 12e16 weeks65 that most likely reflects
the duration of IgE bound to effector cells and the down-
regulation of Fc3RI receptors on these cells. A pooled analysis
of two multicentre, double-blind, randomized, placebo-
controlled, phase III studies showed that the response to
omalizumab was characterized by a progressive onset, with
38% of patients responding within 4 weeks of initiating
treatment, compared with 64% at week 16.66 In this analysis,
responders were classified according to a composite measure
(no exacerbations and one or more of the following: reduced
symptoms, reduced rescue medication use, improved lung
function, improved quality of life). In patients who were
responders at 16 weeks, only 61% had responded at 4 weeks,78% had responded by 8 weeks and 87% had responded by 12
weeks. Therefore, assessing response before 16 weeks may
not identify 100% of patients who would respond to omali-
zumab. It is noteworthy that a quarter of the 28 patients who
discontinued treatment due to an unsatisfactory effect in the
historic-prospective French study had been treated for less
than 16 weeks.58
The measure of evaluating patients’ response to omali-
zumab using the physician’s overall assessment will be
further tested in the Evaluate Xolair for Asthma as Leading
Treatment (EXALT) study of 400 patients with severe
persistent allergic asthma treated with high-dose ICS plus
a LABA, and to which omalizumab is added.67 The study will
assess how well a response at 16 weeks can also predict
a response at 32 weeks. It will also examine whether the
predictive power of the response measure can be further
improved with the addition of further outcome measures,
such as lung function, quality of life and asthma symptoms.Duration of treatment and potential for dose
reduction
Omalizumab is intended for long-term control of asthma
and its efficacy and safety have been maintained in three
long-term (i.e. 52-week) studies.63,68,69 Additionally, with-
drawal of treatment is not associated with AEs. In one study
extension, after a 12-week washout period before restart-
ing omalizumab, AEs were found to be similar between
omalizumab and control, and similar to those observed in
the core study. No adverse effect on the safety profile was
noted.70 During the clinical trials programme, after core
treatment periods of 28e52 weeks, no evidence of with-
drawal or rebound effects was seen during follow-up
periods of 12e24 weeks (Novartis, data on file).
Figure 6 UK responder algorithm.64
1108 S. Holgate et al.It has been suggested that it may be possible to reduce
omalizumab doses using a stepping down strategy, once
asthma control has been improved. However, reducing
omalizumab doses below those in the dosing table is not
recommended as the resulting increase in free IgE leads todeterioration of asthma control.71 A pharmacokinetic/
pharmacodynamic model-based study used data from the
INNOVATE study39 and the 16-week follow-up period along
with data from a single-dose bioequivalence study (Novar-
tis, data on file) to plot free IgE, omalizumab and total IgE
Omalizumab in clinical practice 1109concentrations against changes in measures of asthma
control (total asthma symptom score, morning PEF and
rescue medication use).71 Model-derived omalizumab and
free IgE concentrations correlated well with changes in
clinical outcomes. Following treatment cessation, free IgE
and omalizumab concentrations returned towards baseline
and asthma symptoms re-emerged.71 It is therefore rec-
ommended that omalizumab continues to be administered
in accordance with the dosing table in those patients who
respond and for as long as they continue to benefit from this
treatment.
The ongoing EXCELS study will provide additional infor-
mation on long-term efficacy and safety. EXCELS is
a prospective, observational cohort study of non-omalizu-
mab and omalizumab-treated patients from US clinical
practices and is designed to characterize the long-term
safety and effectiveness of omalizumab in up to 7500
patients during 5 years of follow up10.Comedications
In the EU, omalizumab is intended for use in conjunctionwith
ICS and LABA. Nevertheless, in three studies omalizumab has
been shown to reduce ICS requirements. In one randomized,
double-blind, placebo-controlled study, median reductions
in fluticasone dose were significantly greater with omalizu-
mab than placebo (60% vs 50%; PZ 0.003).72 The trial
involved a 16-week add-on phase and a 16-week fluticasone
reduction phase. The large reduction in fluticasone dose in
the placebo group was attributed to increased compliance
with other controller medication in the clinical trial setting.
Similar findings were reported in another study that also
included a 12-week ICS reduction phase after 16 weeks of
add-on omalizumab therapy; reductions in beclometasone
dipropionate doses were significantly greater in patients
receiving omalizumab (median 75%) than in those receiving
placebo (50%; P< 0.001).73 Omalizumab recipientswere also
more likely to discontinue ICS therapy (39.6%) than those
receiving placebo (19.1%; P< 0.001). Again, a reduction in
the corticosteroid dose was observed in the placebo group,
presumably due to increased compliance. These findings are
supported by those of a third study, which included an 8-
week ICS reduction phase after 16 weeks of add-on omali-
zumab therapy.74 Patients receiving omalizumab required
lower beclometasone doses at the end of the corticosteroid-
reduction phase (median 100 mg) than those receiving
placebo (300 mg). Although these studies have shown that ICS
dose reductions can be achieved in patients receiving add-on
omalizumab therapy, it is important to remember that
omalizumab is intended for use in conjunction with inhaled
ICS and LABA in the EU (the US label does not require patients
to be receiving a LABA). In addition, any decrease in ICS
should be under the direct supervision of a physician, and
needs to be performed gradually.
In the INNOVATE study, all patients were receiving high-
dose ICS plus LABA.39 However, approximately 60% of
patients were also receiving additional controller medica-
tion (including maintenance OCS [22%], LTRAs [35%] and
theophylline [27%]). Omalizumab has been shown to be
effective in patients with severe persistent allergic asthma
regardless of baseline OCS use. In a pooled analysis of sevencontrolled trials, omalizumab reduced exacerbation rates by
37% in patients who required OCS and by 39% in thosewho did
not.75 Omalizumab can, therefore, be considered for the
treatment of inadequately controlled severe persistent
allergic asthma, regardless of OCS use. A planned study of
450 patients in a naturalistic setting, which will include
100 OCS-dependent patients, is expected to provide further
information on OCS use during treatment with omalizumab.
Omalizumab has been shown to significantly reduce the
need for rescue OCS bursts irrespective of LTRA use. In
a pooled analysis of three randomized trials, omalizumab
reduced the need for OCS bursts by 51% in non-LTRA users
(relative risk [omalizumab vs standard care]: 0.49; 95% CI
0.34e0.71; P< 0.0001) and by 53% in LTRA users (relative
risk: 0.47; 95% CI 0.32e0.68; P< 0.0001).76Effectiveness in clinical practice
Between June 2003 and April 2007, an estimated 63,000
patients with moderate-to-severe or severe persistent
allergic asthma who are not adequately controlled on
standard therapy have been treated with omalizumab
worldwide, and more than 5000 patients received omali-
zumab in clinical trials. Several observational studies have
provided data on the real-world effectiveness of
omalizumab.
In the French historic-prospective study, the annual exac-
erbation ratedecreasedby62% (6.0e2.3), emergency visits by
65% (3.1e1.1) and hospitalizations by 29% (1.7e1.2) for the
146 patients who had been prescribed omalizumab for severe
allergic asthma between July 2003 and January 2006.58
Compared with the year before treatment, the percentage of
patients who did not have an asthma exacerbation during
treatmentmore than doubled; those not having an emergency
visit increased by 69%; and those not requiring hospitalization
increasedby53%.Additionally, 25.6%ofpatients stoppedusing
or lowered the dose of ICS, and 48.1% reduced or discontinued
maintenance OCS. Overall, 26.5% of patients experienced at
least one AE, and five patients experienced a severe AE. The
most frequently reported AEs were headache (nZ 12),
asthenia (nZ 6), local injection-site reaction (nZ 5) and
nausea (nZ 5). Severe AEs were asthenia, irritability, head-
ache, hypersensitivity convulsions, myalgia, arthralgia and
periarthritis. Only two patients who experienced a severe AE
discontinued treatment.
A German 6-month follow-up study conducted between
2005 and 2007 in 280 omalizumab-treated patients with
severe persistent allergic IgE-mediated asthma reported
marked reductions in daily symptoms (76%), nocturnal
symptoms (84%), exacerbations (82%), unscheduled health-
care contacts (81%) and hospitalizations (78%).77 Mean Mini-
AQLQ score increased from2.9 to 4.5, and treatment efficacy
was rated as excellent or good by both physicians and
patients (82% and 86%, respectively), thus confirming the
clinically relevant effect of omalizumab. In this study,
omalizumab-related AEs were reported in 7% of patients.
A small questionnaire-based observational study in 65
patients in the UK, who had continued with omalizumab
therapy beyond 16 weeks found that out of 33 patients
taking OCS at baseline, 18 (54.5%) had reduced their OCS
and eight (24.2%) had stopped OCS altogether. The mean
1110 S. Holgate et al.relative reduction in OCS dose from baseline was 49%
(22.6e11.6 mg, prednisolone equivalent).78
In the USA, omalizumab has been successfully adopted
as a second-line therapy for inadequately controlled
moderate or severe asthma in allergy and pulmonary
practices.79 Further data on the long-term (5 years) effi-
cacy and safety of omalizumab in US clinical practices will
be available upon completion (sometime after 2011) of the
EXCELS study10.
Comorbidity
Omalizumab has been shown to provide clinical benefits for
comorbid conditions that frequently occur in patients with
asthma. For example, omalizumab has been shown to be
effective in the treatment of allergic rhinitis, which
frequently coexists with asthma and is thought to share
a common allergic inflammatory cause centred on IgE.80
Omalizumab treatment results in substantial improvements
in nasal symptoms, quality of life and rescue antihistamine
use compared with placebo or specific immunotherapy in
patients with allergic rhinitis.37,81,82 A study has also shown
that in patients with co-existing asthma and rhinitis, oma-
lizumab treatment significantly reduces asthma, rhinitis
and asthma/rhinitis composite symptom scores compared
with placebo (P 0.02).83 Furthermore, analysis has shown
that omalizumab-treated asthma ‘‘responders’’ (i.e.
demonstrating a marked improvement in asthma control or
complete asthma control according to the physician’s
overall assessment) were more likely to experience
a rhinitis response than omalizumab-treated asthma non-
responders: the odds ratio for a 1.0-point improvement in
the Rhinitis Quality of Life Questionnaire (RQLQ) overall
score84 in asthma responders vs non-responders was 3.56
(95% CI 1.94e6.54) and for a 1.5-point improvement in the
RQLQ overall score the odds ratio was 3.79 (95% CI 2.11e
6.82).85
Although omalizumab is not indicated for the treatment of
allergic rhinitis, it may provide additional benefits in patients
with severe persistent allergic asthma and concomitant
rhinitis, particularly in patients who achieve a marked
improvementor complete asthmacontrolwithomalizumab.85
Discussion
Omalizumab has been successfully adopted into clinical
practice, with more than 68,000 patients treated world-
wide since June 2003. Observational studies have shown
important benefits for many patients with inadequately
controlled severe persistent allergic asthma who respond
to omalizumab therapy. This supports the results from the
comprehensive clinical trial programme, in which omali-
zumab significantly reduced asthma exacerbation and
emergency visit rates, and significantly improved quality
of life in patients with severe persistent allergic asthma.
Consequently, omalizumab is indicated in the EU as
add-on therapy to improve control of severe persistent
allergic asthma that remains inadequately controlled
despite treatment with high-dose ICS and a LABA. In 2007,
the UK National Institute for Health and Clinical Excel-
lence (NICE) approved public reimbursement of add-onomalizumab for the treatment of severe persistent
allergic (IgE-mediated) asthma where, in addition to the
label criteria, patients should have experienced two or
more severe exacerbations requiring hospitalization
within the previous year, or three or more severe exac-
erbations within the previous year, one requiring hospi-
talization, and two requiring treatment or monitoring in
an accident and emergency unit.86 The label in the US is
different; omalizumab is indicated for moderate-to-
severe asthma that is uncontrolled despite treatment with
high-dose ICS. In some clinical trials, omalizumab has
demonstrated efficacy in patients with rhinitis and
patients with co-existing asthma and allergic rhinitis,
although it is not indicated for this comorbidity.
Analyses of patients treated in clinical trials have
shown that it is difficult to predict which patients, within
the label population, will derive greatest benefit from
omalizumab based on pre-treatment patient characteris-
tics. In the EU, it is recommended that treatment is
initiated in eligible patients and the response evaluated
by the physician after 16 weeks of therapy. Treatment
should be continued in patients who are judged by the
physician to have achieved a marked improvement or
complete asthma control. Using this method of assess-
ment, the analysis by Bousquet et al. indicates that
approximately 60% of patients could be expected to be
identified as responders to omalizumab.56
It is recommended that omalizumab be dosed
according to the patient’s body weight and pre-treat-
ment total IgE levels (30e700 IU/mL) using the dosing
table (Fig. 5). Omalizumab is administered by subcuta-
neous injection every 2 or 4 weeks and should be
continued in those patients who respond for as long as
they continue to benefit from this treatment. Reducing
the omalizumab dose can cause deterioration of asthma
control and is not recommended. A small study has found
that 1 year after cessation of omalizumab following 6
years of treatment, patients’ asthma symptoms were
similar to when they were receiving omalizumab,87 indi-
cating that omalizumab has the potential to actually
modify the disease. Basophil reactivity was also signifi-
cantly reduced compared with controls (P< 0.001).
Although omalizumab therapy may potentially have some
disease-modifying properties, further investigation is
needed. A prospective study is currently underway that
aims to assess the effect of 78 weeks of omalizumab
therapy on airway sub-epithelial eosinophils and other
markers of airway inflammation and remodelling, through
the collection of bronchial biopsies and induced sputum
samples.
The reason why not all patients respond to omalizumab
therapy is unclear. In clinical practice, correct diagnosis of
allergic (IgE-mediated) asthma is essential, and potential
comorbidities should be considered. One study reported
that 12% of patients with difficult-to-treat asthma who
remained symptomatic despite treatment with >1000 mg
beclometasone dipropionate (or equivalent) and a LABA did
not have asthma, and a further 7% had additional diagnoses
such as bronchiectasis or hypereosinophilia.88 Analysis of
INNOVATE data has shown that IgE is equally well sup-
pressed in omalizumab responders and non-responders.71
Therefore, if patient selection and omalizumab
Omalizumab in clinical practice 1111administration are correct, it may be that IgE is not driving
asthma in some of these cases.
Overall, by careful patient selection and dosing, and
monitoring of patients following administration, omalizu-
mab can be effectively and safely administered, and
control of a high proportion of persistent severe allergic
asthma cases can be successfully achieved.Acknowledgements
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